Breaking News Instant updates and real-time market news.

TEVA

Teva

, AGN

Allergan

$245.71

-0.02 (-0.01%)

12:55
07/19/17
07/19
12:55
07/19/17
12:55

Piper Jaffray specialty pharma analysts hold an analyst/industry conference call

Specialty Pharmaceuticals Analysts, along with a Key Opinion Leader in migraines, discuss the emerging anti-CGRP class for migraine prophylaxis (e.g., TEVA's fremanezumab), as well as the potential role of anti-CGRP agents in acute treatment (e.g., AGN's ubrogepant) and the potential impact of the anti-CGRP class on currently available agents (e.g., AGN's Botox) and other agents recently approved (e.g., SUPN's Trokendi XR) or are in late-stage development (e.g., Zosano's M207) on an Analyst/Industry conference call to be held on July 19 at 1:30 pm.

TEVA

Teva

AGN

Allergan

$245.71

-0.02 (-0.01%)

SUPN

Supernus

$43.05

1.1 (2.62%)

ALDR

Alder Biopharmaceuticals

$11.55

-0.3 (-2.53%)

AMGN

Amgen

$177.48

0.08 (0.05%)

LLY

Eli Lilly

$83.83

0.13 (0.16%)

ZSAN

Zosano Pharma

$1.34

0.02 (1.52%)

  • 19

    Jul

  • 19

    Jul

  • 25

    Jul

  • 25

    Jul

  • 27

    Jul

  • 03

    Aug

  • 03

    Aug

  • 03

    Aug

  • 14

    Aug

  • 30

    Aug

  • 11

    Sep

  • 14

    Sep

  • 03

    Feb

TEVA Teva

07/18/17
WELS
07/18/17
NO CHANGE
WELS
Market Perform
Novartis report has cautious read-through for Mylan, Teva, says Wells Fargo
Wells Fargo analyst David Maris noted that Novartis' (NVS) Sandoz unit is one of the world's largest generic drug makers and he believes the proper read-through from its report is that the U.S. generic market remains challenging and that investors should remain cautious on the generics space. Maris, who said he would not be surprised to see Mylan (MYL) or Teva (TEVA) weaker following Novartis' report, keeps Market Perform ratings on those two names.
07/13/17
SBSH
07/13/17
NO CHANGE
Target $42
SBSH
Buy
Teva landing Soriot would be 'material positive,' says Citi
Citi analyst Liav Abraham believes Calcalist's report of Teva (TEVA) hiring away AstraZeneca's (AZN) CEO Pascal Soriot has credibility given the "relatively accurate track record" of the Israeli press in the "leaking" of information pertaining to Teva. The news, if confirmed, would be a "material positive" for Teva over the near to medium term, Abraham tells investors in a research note. She believes Soriot would "lend significant credibility" to Teva's turnaround thesis. On the other side, Soriot leaving would increase concerns over the pending outcome of AstraZeneca's MYSTIC trial, which constitutes the dominant near-term driver for the shares, Abraham argues. She has a Buy rating on Teva with a $42 price target. The stock in premarket trading is up 2% to $32.80. AstraZeneca is down 14c to $32.78.
07/13/17
LEER
07/13/17
NO CHANGE
LEER
Outperform
AstraZeneca CEO departure now would have 'terrible' optics, says Leerink
Leerink analyst Seamus Fernandez said the media report that AstraZeneca (AZN) CEO Pascal Soriot may be leaving the company to take over at Teva (TEVA) comes as a "major surprise," adding that while the company would not comment to him on the rumor it also did not outright deny the report. While the news does not appear to be related to the outcome of the MYSTIC trial in non-small cell lung cancer, the optics around such a departure at this would be "terrible" and his loss would be a "clear negative" for AstraZeneca, according to Fernandez, who has an Outperform rating on Astra shares.
07/05/17
OPCO
07/05/17
NO CHANGE
Target $70
OPCO
Outperform
Neurocrine Ingrezza 'holds steady' after competitor data, says Oppenheimer
Oppenheimer analyst Jay Olson notes that Teva's (TEVA) Austedo could become a competitor to Neurocrine's (NBIX) Ingrezza with a PDUFA date for the tardive dyskinesia indication on August 30, 2017. However, the analyst sees Ingrezza as well positioned and reiterates an Outperform rating and $70 price target on Neurocrine's shares. A key factor to follow beyond the short trials will be real-life performance considering the number needed to treat to observe a 50% AIMS improvement was 5 for Austedo and 4 for Ingrezza, he contends.
AGN Allergan
$245.71

-0.02 (-0.01%)

06/16/17
CANT
06/16/17
INITIATION
Target $231
CANT
Neutral
Allergan initiated with a Neutral at Cantor
Cantor Fitzgerald analyst Louise Chen started Allergan with a Neutral rating and $231 price target.
06/29/17
FBCO
06/29/17
NO CHANGE
Target $64
FBCO
Outperform
Sarepta selection of veteran CEO a positive, says Credit Suisse
Credit Suisse analyst Alethia Young said Sarepta's (SRPT) selection of Doug Ingram, an established industry veteran and a former president at Allergan (AGN), as its new CEO is a positive, noting that Ingram has experience both in the CNS space and at running a large scale pharmaceutical company. Young, who would guess that the hiring will be viewed positively and sees Sarepta shares trading up following the news, keeps an Outperform rating and $64 price target on the stock.
06/29/17
COWN
06/29/17
NO CHANGE
Target $400
COWN
Outperform
Allergan could emerge winner in migraine paradigm, says Cowen
Cowen analyst Ken Cacciatore believes Allergan's presence in the migraine space should continue to strengthen in the near-term via continued Botox growth and in the longer-term via oral CGRP's. He believes the introduction of injectable CGRP's could actually create managed care increased utilization of Botox. Cacciatore reiterated his Buy rating and $400 price target on Allergan shares.
07/06/17
BERN
07/06/17
NO CHANGE
BERN
Allergan Q2 aesthetics survey mixed, says Bernstein
Bernstein analyst Aaron (Ronny) Gal says a survey of 100 high volume U.S. aesthetic physicians. in late June showed that Allergan's U.S. toxin market is growing above average levels, as more younger women and men are using its products. Gal adds that the line filler market "continues to grow well with 6%-12% sequential growth," as "Juvederm is gaining share" and doing well with men and women under 30. However, the analyst adds that the growth of Allergan's Kybella treatment is "modest," with the treatment increasingly seen as a "niche" offering. But Zeltiq is growing 9% sequentially, he added. Gal keeps a $296 price target and an Outperform rating on Allergan.
SUPN Supernus
$43.05

1.1 (2.62%)

07/14/17
JANY
07/14/17
INITIATION
Target $47
JANY
Neutral
Supernus initiated with a Neutral at Janney Capital
Janney Capital started Supernus with a Neutral rating and $47 fair value estimate.
07/17/17
PIPR
07/17/17
DOWNGRADE
Target $46
PIPR
Neutral
Supernus downgraded to Neutral from Overweight at Piper Jaffray
Piper Jaffray analyst David Amsellem downgraded Supernus Pharmaceuticals to Neutral and raised his price target for the shares to $46 from $44. The analyst sees "muted" prospects for "significant value creation" in the second half of 2017 due to valuation and the wider spread between gross and net sales amid Trokendi promotions.
07/14/17
07/14/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Safety, Income and Growth (safe) initiated with a Buy at Ladenburg. 2. News Corp. (NWSA) initiated with a Buy at Rosenblatt. 3. Woodward (WWD) initiated with an Outperform at Oppenheimer. 4. CBL & Associates (CBL) coverage resumed with a Hold at Stifel. 5. Supernus (SUPN) initiated with a Neutral at Janney Capital. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
07/05/17
CANT
07/05/17
NO CHANGE
CANT
Supernus price target raised to $49 from $34 at Cantor
After traveling with Supernus' management, Cantor analyst William Tanner says that the company's SPN-810 and SPN-812 drugs "could possess significant commercial potential as treatments for impulse aggression in ADHD and as a non-stimulant for the treatment of ADHD symptoms, respectively." He thinks that the company's Trokendi XR drug "will continue to gain traction as a prevention for migraine," The analyst raised his price target on the stock to $49 from $34 and keeps a Buy rating on the shares.
ALDR Alder Biopharmaceuticals
$11.55

-0.3 (-2.53%)

06/28/17
06/28/17
DOWNGRADE

On The Fly: Top five analyst downgrades
Catch up on today's top five analyst downgrades with this list compiled by The Fly: 1. Qualcomm (QCOM) downgraded to Market Perform from Outperform at Northland with analyst Tom Sepenzis citing the previous guidance change due to the dispute with Apple (AAPL) and its suppliers. The analyst is uncertain Qualcomm's model will survive multiple attacks from regulators and now Apple, and said the longer the fight with Apple goes on the more the negative impact on shares will be. 2. Alder Biopharmaceuticals (ALDR) downgraded to Neutral from Outperform at Credit Suisse with analyst Vamil Divan citing the release of data from the PROMISE-1 trial of eptinezumab in frequent migraine treatment. Divan lowered his price target on Alder shares to $17 from $30. 3. Advance Auto Parts (AAP) downgraded to Neutral from Buy at Cleveland Research with the firm saying checks indicate that second quarter comparables are likely running below consensus as industry weakness pressures sales trends. 4. Brookfield Renewable (BEP) downgraded to Neutral from Outperform at Macquarie with analyst David Noseworthy citing expectations that growth in the U.S. will slow after the closing of the TerraForm Power (TERP) and TerraForm Global (GLBL) acquisitions, risk from increasing exposure to developing market, and premium valuation. 5. First Data (FDC) downgraded to Equal Weight from Overweight at Morgan Stanley with analyst James Faucette saying the turnaround in fundamentals is largely reflected in shares and deleveraging potential is less likely to be a driver going forward. This list is just a portion of The Fly's full analyst coverage. To see The Fly's full Street Research coverage, click here.
06/28/17
FBCO
06/28/17
DOWNGRADE
Target $17
FBCO
Neutral
Alder Biopharmaceuticals downgraded to Neutral from Outperform at Credit Suisse
Credit Suisse analyst Vamil Divan downgraded Alder Biopharmaceuticals to Neutral from Outperform following the release of data from the PROMISE-1 trial of eptinezumab in frequent migraine treatment. While Divan finds some optimism, especially in the speed of onset and depth of response seen in a subset of patients, he sees challenges getting the company's "more nuanced message" communicated in a crowded migraine market, he tells investors. Divan lowered his price target on Alder shares to $17 from $30.
06/28/17
WELS
06/28/17
NO CHANGE
WELS
Alder Biopharmaceuticals should be bought on weakness, says Wells Fargo
Wells Fargo recommends buying Alder on weakness following the release of data on the company's eptinezumab IV in frequent episodic migraine. The firm says that the drug's reduction "of mean placebo adjusted rmigraine days are in-line with prior Phase 2 results and in the range of that seen with competitors." The analyst says that the drug's fast onset versus competitors and 75% response rate after four weeks should "at minimum support a competitive frontline position and dominant 2nd line position for migraine prevention." It keeps an Outperform rating on the stock.
07/10/17
WELS
07/10/17
NO CHANGE
WELS
Alder outlook remains positive despite concerns, says Wells Fargo
Wells Fargo says that the market has been concerned about the efficacy of Alder Biopharmaceuticals' migraine treatment, eptinezumab, since Phase 3 data on the drug was released. But the firm says that the company's subcutaneous strategy appears to be more developed than the market realizes, as the company could release 100 mg and 300 mg subcutaneous versions of the drug. The firm thinks that the IV version of the drug could obtain 10%-20% of the frontline market, driven by physician economics and its speed of onset. Wells adds that the drug "could be dominant" among patients looking to switch to a new migraine treatment after another drug or drugs failed to work, and it thinks that a subcutaneous version of eptinezumab could enable the drug's market share to rise. Wells keeps an Outperform rating on the stock.
AMGN Amgen
$177.48

0.08 (0.05%)

07/17/17
JEFF
07/17/17
NO CHANGE
Target $195
JEFF
Buy
Amgen Complete Response Letter was expected, says Jefferies
Jefferies analyst Michael Yee says the FDA's Complete Response Letter for Amgen's Romosozumab in osteoporosis was expected. The indication is not in current consensus near-term estimates given the prior known imbalance in safety signal, Yee tells investors in a research note. He believes the drug could still be approved in 2018-2019 based on a good risk/benefit profile. The analyst has a Buy rating on Amgen with a $195 price target.
07/18/17
CHLM
07/18/17
NO CHANGE
Target $160
CHLM
Buy
Craig-Hallum sees Ligand agreement with Amgen as 'incrementally' positive news
Craig-Hallum analyst Matt Hewitt notes that Ligand (LGND) announced that it had entered into a new commercial license and supply agreement with Amgen (AMGN) for the use of the former's Captisol technology in the formulation of AMG 330, a bispecific antibody being investigated as a treatment for acute myeloid leukemia. The analyst believes this agreement signals AMG 330 moving from Phase 1 into Phase 2 trials and incrementally positive news for Ligand as this news was not anticipated in his model. Hewitt reiterates a Buy rating and $160 price target on Ligand's shares.
07/18/17
PIPR
07/18/17
NO CHANGE
Target $14
PIPR
Overweight
Piper says Array deal with Amgen 'another example' of successful partnering
Commenting on Array Biopharma's (ARRY) announcement of a preclinical autoimmune partnership deal with Amgen (AMGN), Piper Jaffray analyst Edward Tenthoff called the agreement "yet another example of Array successfully partnering its discoveries" and raising non-dilutive capital. Tenthoff keeps an Overweight rating and $14 price target on Array Biopharma shares.
07/10/17
JEFF
07/10/17
INITIATION
Target $195
JEFF
Buy
Amgen assumed with a Buy at Jefferies
Jefferies analyst Michael Yee assumed coverage on Amgen with a Buy and a $195 price target.
LLY Eli Lilly
$83.83

0.13 (0.16%)

07/17/17
PIPR
07/17/17
NO CHANGE
Target $102
PIPR
Overweight
Eli Lilly's launch in type 2 diabetes 'remarkable,' says Piper Jaffray
Piper Jaffray analyst Richard Purkiss is highlighting the "remarkable growth story" of Eli Lilly's (LLY) once-weekly GLP-1 agonist Trulicity for type 2 diabetes. At its current pace, Trulicity would become market leader in the GLP-1 space in the early part of next year, surpassing Novo Nordisk's (NVO) Victoza, Purkiss tells investors in a research note. He views Lilly's launch as "quite simply unique in the current climate." Lilly remains one of the analyst's top 2017 picks with an Overweight rating and $102 price target.
07/14/17
WELS
07/14/17
NO CHANGE
WELS
Underperform
J&J approval another negative for Valeant, says Wells Fargo
Wells Fargo analyst David Maris says Valeant Pharmaceuticals (VRX) has a new competitor in the psoriasis space after the FDA yesterday approved Tremfya from Johnson & Johnson (JNJ). The news is another negative for Valeant, which is about to launch its own psoriasis treatment, Siliq, in the second half of 2017, Maris tells investors in a research note. With Talz from Eli Lilly (LLY), Humira from AbbVie (ABBV), Cosentyx from Novartis (NVS) and now J&J as a new competitor, Valeant is unlikely to be competitive in the psoriasis market, Maris contends. He believes his peak sales estimate of $250M for Siliq may prove optimistic given the competition. Maris an Underperform rating on Valeant with a $9 price target. The drugmaker closed yesterday at $17.29.
06/27/17
06/27/17
NO CHANGE

Large cap pharma could benefit from upcoming executive order, says Wells Fargo
Wells Fargo says that, based on press reports, large cap pharma could benefit from President Trump's upcoming executive order on drug pricing. The firm says the articles indicate that the order will not create major reforms or do anything to lower consumers' costs or solve current pricing issues. Publicly traded companies in the space include AstraZeneca (AZN), Bristol-Myers (BMY), Eli Lilly (LLY), GlaxoSmithKline (GSK), Johnson & Johnson (JNJ), Merck (MRK), Novartis (NVS), Pfizer (PFE), Roche (RHHBY) and Sanofi (SNY).
06/14/17
RHCO
06/14/17
NO CHANGE
RHCO
Eli Lilly has positive read through from J&J data, says SunTrust
SunTrust analyst John Boris says that data for Johnson & Johnson's (JNJ) Invokana for diabetes represented a best-case scenario for Eli Lilly (LLY). J&J's drug "significantly reduced the combined risk of cardiovascular death, myocardial infarction and nonfatal stroke in diabetes patients at risk for or with a history of CV diseases," and its efficacy on CV death is positive for the SGLT-2 class, to which Eli Lilly's Jardiance also belongs, according to the analyst. But the data leaves Jardiance, which reduced CV death by a statistically significant 38% versus Invokana's non-significant 13%, as the best in the class, wrote the analyst, who reiterates a $101 price target and a Buy rating on Eli Lilly.
ZSAN Zosano Pharma
$1.34

0.02 (1.52%)

08/11/16
LTCO
08/11/16
DOWNGRADE
LTCO
Neutral
Zosano Pharma downgraded to Neutral from Buy at Ladenburg
Ladenburg Thalmann analyst Matt Kaplan downgraded Zosano Pharma to Neutral saying the company will need to raise "significantly more cash" for operations in 2017. The analyst is also uncertain about Zosano's market opportunity.
03/24/17
PIPR
03/24/17
INITIATION
Target $4
PIPR
Overweight
Zosano Pharma initiated with an Overweight at Piper Jaffray
Piper Jaffray analyst Charles Duncan started Zosano Pharma with an Overweight rating and $4 price target. The analyst sees the company's lead candidate M207, a zolmitriptan patch for acute migraine, as differentiated on speed of efficacy and convenient formulation.
03/24/17
03/24/17
INITIATION

On The Fly: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. American Express (AXP) initiated with a Neutral at Tigress Financial. 2. Zosano Pharma (ZSAN) initiated with an Overweight at Piper Jaffray. 3. SkyWest (SKYW) initiated with an In-Line at Imperial Capital. 4. Statoil (STO) initiated with an Underperform at Macquarie. 5. Cogent (CCOI) initiated with a Buy at Deutsche Bank. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.

TODAY'S FREE FLY STORIES

UAL

United Continental

$63.93

-4.06 (-5.97%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Hot Stocks
United Continental says Q3 involuntary denied boardings down 92% y/y »

Says employees…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

VRX

Valeant

$12.10

-0.29 (-2.34%)

10:40
10/19/17
10/19
10:40
10/19/17
10:40
Options
Higher options volume in Valeant as one player banks a big profit »

Higher options volume in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Nov

BP

BP

$38.81

0.09 (0.23%)

10:36
10/19/17
10/19
10:36
10/19/17
10:36
Hot Stocks
BP chairman Carl-Henric Svanberg announces intention to retire »

BP announces that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MON

Monsanto

$121.99

-0.09 (-0.07%)

, AGCO

Agco

$70.84

-0.91 (-1.27%)

10:33
10/19/17
10/19
10:33
10/19/17
10:33
Hot Stocks
Monsanto's Climate Corp announces data connectivity agreement with Agco »

The Climate Corporation,…

MON

Monsanto

$121.99

-0.09 (-0.07%)

AGCO

Agco

$70.84

-0.91 (-1.27%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 31

    Oct

FCEL

FuelCell

$2.13

0.09 (4.41%)

10:31
10/19/17
10/19
10:31
10/19/17
10:31
Hot Stocks
FuelCell to supply power to Navy base in Connecticut »

FuelCell Energy announced…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 16

    Nov

10:30
10/19/17
10/19
10:30
10/19/17
10:30
General news
EIA natural gas storage change for week ending October 13 »

Gas inventories 51 Bcf…

MU

Micron

$41.65

1.26 (3.12%)

10:30
10/19/17
10/19
10:30
10/19/17
10:30
Options
Active trading in Micron calls as shares slump Thursday »

Active trading in Micron…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 23

    Oct

NKE

Nike

$52.21

-0.0915 (-0.17%)

, ADDYY

adidas

$112.54

-0.08 (-0.07%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Hot Stocks
Goldman Sachs cuts Nike rating ahead of investor day on excess inventory »

This morning, Goldman…

NKE

Nike

$52.21

-0.0915 (-0.17%)

ADDYY

adidas

$112.54

-0.08 (-0.07%)

GRPN

Groupon

$5.00

0.05 (1.01%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 25

    Oct

  • 01

    Nov

  • 16

    Nov

ULTA

Ulta Beauty

$200.90

2.59 (1.31%)

10:29
10/19/17
10/19
10:29
10/19/17
10:29
Rumors
Rumor moving shares of Ulta Beauty »

Rumor: Ulta Beauty…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

10:25
10/19/17
10/19
10:25
10/19/17
10:25
General news
Today's U.S. reports »

Today's U.S. reports…

UAL

United Continental

$64.26

-3.73 (-5.49%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Technical Analysis
Technical View: United Continental falls after results and outlook »

The company reported Q3…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

MEIP

MEI Pharma

$2.48

0.15 (6.44%)

10:23
10/19/17
10/19
10:23
10/19/17
10:23
Hot Stocks
MEI Pharma's pracinostat granted EU orphan designation »

Pracinostat was granted…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VZ

Verizon

$50.08

1.431 (2.94%)

10:20
10/19/17
10/19
10:20
10/19/17
10:20
Options
Notable ratio spread in Verizon as shares rally on earnings »

Notable ratio spread in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Oct

  • 01

    Nov

10:20
10/19/17
10/19
10:20
10/19/17
10:20
General news
Treasury Action: yields resumed their slide »

Treasury Action: yields…

$NSD

NASDAQ Market Internals

10:17
10/19/17
10/19
10:17
10/19/17
10:17
Technical Analysis
NASDAQ market internals summary »

Volume is above average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

$NYE

NYSE Market Internals

10:16
10/19/17
10/19
10:16
10/19/17
10:16
Technical Analysis
NYSE market internals summary »

Volume is below average…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

MRK

Merck

$63.76

0.25 (0.39%)

, TEVA

Teva

$14.61

-0.01 (-0.07%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Periodicals
Merck wins appeal to revive NuvaRing patent case against Teva, Bloomberg says »

An appeals court said a…

MRK

Merck

$63.76

0.25 (0.39%)

TEVA

Teva

$14.61

-0.01 (-0.07%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Oct

  • 23

    Oct

  • 27

    Oct

  • 02

    Nov

  • 06

    Nov

  • 08

    Nov

  • 16

    Nov

  • 30

    Nov

  • 02

    Feb

ADP

ADP

$113.93

0.21 (0.18%)

10:15
10/19/17
10/19
10:15
10/19/17
10:15
Hot Stocks
Pershing Square releases additional questions for ADP »

Pershing Square Capital…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 02

    Nov

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
U.S. leading economic index fell 0.2% to 128.6 in September »

U.S. leading economic…

10:15
10/19/17
10/19
10:15
10/19/17
10:15
General news
Breaking General news story  »

Week of 10/13 EIA Natural…

GS

Goldman Sachs

$240.07

-1.96 (-0.81%)

10:13
10/19/17
10/19
10:13
10/19/17
10:13
Hot Stocks
Blankfein: 'Just left Frankfurt,' 'I'll be spending a lot more time there' »

Goldman Sachs Chairman…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 22

    Oct

  • 23

    Oct

EVHC

Envision Healthcare

$40.70

0.05 (0.12%)

10:11
10/19/17
10/19
10:11
10/19/17
10:11
Periodicals
Starboard's Smith to pitch Envision Healthcare as long idea, Bloomberg says »

Starboard Value's…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 01

    Nov

NNI

Nelnet

$51.05

-0.27 (-0.53%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Upgrade
Nelnet rating change  »

Follow-up: Nelnet…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CZR

Caesars

$12.30

0.4 (3.36%)

10:10
10/19/17
10/19
10:10
10/19/17
10:10
Options
Short-term call buyer in Ceaser's opens a notable new position »

Short-term call buyer in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 08

    Nov

MMP

Magellan Midstream

$67.56

-0.96 (-1.40%)

10:09
10/19/17
10/19
10:09
10/19/17
10:09
Hot Stocks
Magellan Midstream raises quarterly distribution to 90.5c per unit »

The board of directors of…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 02

    Nov

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.